ID   RT-4
AC   CVCL_0036
SY   RT4; RT4P
DR   BTO; BTO:0002870
DR   CLO; CLO_0008892
DR   EFO; EFO_0006480
DR   CLDB; cl4197
DR   CLDB; cl4198
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-7937
DR   ATCC; HTB-2
DR   BCRC; 60111
DR   BCRJ; 0214
DR   BioSample; SAMN03473092
DR   BioSample; SAMN10988330
DR   CCLE; RT4_URINARY_TRACT
DR   CCRID; 3131C0001001200015
DR   CCRID; 3153C0001000000253
DR   Cell_Model_Passport; SIDM01085
DR   ChEMBL-Cells; CHEMBL3307430
DR   ChEMBL-Targets; CHEMBL614884
DR   CLS; 300326/p10281_RT-4
DR   Cosmic; 687455
DR   Cosmic; 715805
DR   Cosmic; 755396
DR   Cosmic; 760479
DR   Cosmic; 845560
DR   Cosmic; 846283
DR   Cosmic; 867839
DR   Cosmic; 925819
DR   Cosmic; 928816
DR   Cosmic; 943749
DR   Cosmic; 1016881
DR   Cosmic; 1046681
DR   Cosmic; 1068091
DR   Cosmic; 1285125
DR   Cosmic; 1285983
DR   Cosmic; 1819325
DR   Cosmic; 1927301
DR   Cosmic; 2037955
DR   Cosmic; 2050460
DR   Cosmic; 2057455
DR   Cosmic; 2444250
DR   Cosmic; 2686112
DR   Cosmic; 2700996
DR   Cosmic-CLP; 687455
DR   DepMap; ACH-000242
DR   DSMZ; ACC-412
DR   ECACC; 91091914
DR   GDSC; 687455
DR   GEO; GSM136232
DR   GEO; GSM763024
DR   GEO; GSM827439
DR   GEO; GSM887553
DR   GEO; GSM888636
DR   GEO; GSM1374859
DR   GEO; GSM1574570
DR   GEO; GSM1670394
DR   IARC_TP53; 21088
DR   KCLB; 30002
DR   LiGeA; CCLE_210
DR   LINCS_LDP; LCL-1717
DR   PharmacoDB; RT4_1334_2019
DR   SKY/M-FISH/CGH; 1462
DR   Wikidata; Q54951351
RX   PubMed=327080;
RX   PubMed=571047;
RX   PubMed=833871;
RX   PubMed=864752;
RX   PubMed=870558;
RX   PubMed=1114348;
RX   PubMed=3518877;
RX   PubMed=3708594;
RX   PubMed=5503601;
RX   PubMed=6220172;
RX   PubMed=6244232;
RX   PubMed=6582512;
RX   PubMed=6823318;
RX   PubMed=7017212;
RX   PubMed=7459858;
RX   PubMed=7787250;
RX   PubMed=8873383;
RX   PubMed=9850064;
RX   PubMed=11207054;
RX   PubMed=11921286;
RX   PubMed=15846775;
RX   PubMed=16885334;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23401075;
RX   PubMed=24018021;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=25997541;
RX   PubMed=26055179;
RX   PubMed=27270441;
RX   PubMed=27397505;
RX   PubMed=28855393;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://www.proteinatlas.org/learn/cellines
WW   https://www.synapse.org/UC25
WW   http://www.cellresource.cn/fdetail.aspx?id=1596
WW   http://www.cellresource.cn/fdetail.aspx?id=3038
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Doubling time: 37 hours (PubMed=3708594); 65.8 hours (PubMed=26055179); ~80 hours (DSMZ).
CC   HLA typing: A*03:01,02:01; B*44:02,44:02; C*05:01,05:01; DQA1*03:02,03:02; DQB1*05:03,05:03 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: FGFR3-TACC3 gene fusion (PubMed=28855393).
CC   Sequence variation: Homozygous for CDKN2A deletion (PubMed=9850064).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=24035680).
CC   Sequence variation: Has no TP53 mutation (PubMed=7787250).
CC   Omics: CNV analysis.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=2.72%; East Asian, South=0%; South Asian=0.98%; European, North=64.69%; European, South=31.61% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7937; true.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=25877200; PubMed=27270441
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 8
ST   D16S539: 9
ST   D18S51: 15,17
ST   D21S11: 30,32.2
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 9,12
ST   D8S1179: 13,15
ST   FGA: 22,24
ST   Penta D: 12 (CLS)
ST   Penta D: 12,13 (PubMed=25877200)
ST   Penta E: 7,10
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 30
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=864752; DOI=10.1093/jnci/58.6.1743;
RA   Marshall C.J., Franks L.M., Carbonell A.W.;
RT   "Markers of neoplastic transformation in epithelial cell lines derived
RT   from human carcinomas.";
RL   J. Natl. Cancer Inst. 58:1743-1751(1977).
//
RX   PubMed=870558; DOI=10.1177/25.4.870558;
RA   Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.;
RT   "Alkaline phosphatase activity in human bladder tumor cell lines.";
RL   J. Histochem. Cytochem. 25:266-274(1977).
//
RX   PubMed=1114348; DOI=10.1126/science.1114348;
RA   Franks L.M., Rigby C.C.;
RT   "HeLa cells and RT4 cells.";
RL   Science 188:168-168(1975).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=5503601; DOI=10.1038/bjc.1970.89;
RA   Rigby C.C., Franks L.M.;
RT   "A human tissue culture cell line from a transitional cell tumour of
RT   the urinary bladder: growth, chromosome pattern and ultrastructure.";
RL   Br. J. Cancer 24:746-754(1970).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6823318; DOI=10.1038/301429a0;
RA   O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.;
RT   "Identity of some human bladder cancer cell lines.";
RL   Nature 301:429-430(1983).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7787250;
RA   Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J.,
RA   Lippa M., Hatzivassiliou G., Tan J.;
RT   "p53 mutations in bladder carcinoma cell lines.";
RL   Oncol. Res. 6:569-579(1994).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=9850064;
RA   Markl I.D.C., Jones P.A.;
RT   "Presence and location of TP53 mutation determines pattern of
RT   CDKN2A/ARF pathway inactivation in bladder cancer.";
RL   Cancer Res. 58:5348-5353(1998).
//
RX   PubMed=11207054; DOI=10.1054/bjoc.2000.1641;
RA   Fujiyama C., Jones A., Fuggle S., Bicknell R., Cranston D.,
RA   Harris A.L.;
RT   "Human bladder cancer invasion model using rat bladder in vitro and
RT   its use to test mechanisms and therapeutic inhibitors of invasion.";
RL   Br. J. Cancer 84:558-564(2001).
//
RX   PubMed=11921286; DOI=10.1002/gcc.10050;
RA   Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N.,
RA   Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.;
RT   "Molecular genetic analysis of chromosome 9 candidate tumor-suppressor
RT   loci in bladder cancer cell lines.";
RL   Genes Chromosomes Cancer 34:86-96(2002).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182;
RA   Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J.,
RA   Carrato A., Tardon A., Serra C., Real F.X.;
RT   "PIK3CA mutations are an early genetic alteration associated with
RT   FGFR3 mutations in superficial papillary bladder tumors.";
RL   Cancer Res. 66:7401-7404(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403-403(2015).
//
RX   PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002;
RA   Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M.,
RA   Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.;
RT   "Drug-resistant urothelial cancer cell lines display diverse
RT   sensitivity profiles to potential second-line therapeutics.";
RL   Transl. Oncol. 8:210-216(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K.,
RA   Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28855393; DOI=10.1098/rsob.170080;
RA   Sarkar S., Ryan E.L., Royle S.J.;
RT   "FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of
RT   endogenous TACC3 from the mitotic spindle.";
RL   Open Biol. 7:170080.1-170080.11(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//